Transverse Medical
Denver, CO · Healthcare, Other · 9 employees
Transverse Medical Inc. (TMI) is developing the POINT-GUARD™ Cerebral Embolic Protection (CEP) medical device to address the unmet need for Full Brain Protection and the clinical problem of periprocedural Stroke in Structural Heart Procedures, such as Transcatheter Aortic Valve Replacement (TAVR).
Funding history
- Series series b — $10.0M — Apr 2025
- Funding Round — $10.0M — Dec 2024
- Funding Round — $6.6M — Aug 2023
- Series pre-seed — $140K — Nov 2019
- Funding Round — $7.8M — Oct 2018
Recent signals
- Jun 03, 2026: Transverse Medical Appoints Thomas E. Chilcott as Chief Financial Officer
- Apr 29, 2025: Raised $10.0M in Series series b
- Dec 10, 2024: Raised $10.0M
- Aug 18, 2023: Raised $6.6M
- Nov 21, 2019: Raised $140K in Series pre-seed
- Oct 03, 2018: Raised $7.8M
- May 24, 2017: Raised Undisclosed
See plans & pricing → Track Transverse Medical’s funding, hiring, and signals — with verified contacts — on Fundz.